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The nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NF-κB1) is a master regulator of immune and inflammatory responses.
1,2 NF-κB1 belongs to the NF-κB/Rel family of transcription factors that consists of five members in humans:
NF-κB1 (p105/p50), NF-κB2 (p100/p52), RelA, c-Rel, and RelB. The p105 and p100 precursors are proteolytically processed by the proteasome to generate the shorter p50 and p52 isoforms. Homo-and heterodimers are formed by p50, p52 and the Rel proteins. Unstimulated, these dimeric complexes are sequestered in the cytoplasm by inhibitory IκB proteins in an inactive state. Upon stimulation, the phosphorylation and subsequent degradation of IκB proteins is rapidly triggered, releasing the NF-κB/Rel complexes to enter the nucleus where they bind to DNA at κB sites and activate or repress the expression of their target genes. 3 Recently, heterozygous mutations affecting the NFKB1 gene were identified in three human families. Haploinsufficiency of NF-κB1 was causative for combined variable immunodeficiency (CVID) characterized by recurrent infections due to immunoglobulin deficiency (pan-IgG, IgA and/or IgM). 4 We report here on two pediatric patients from unrelated families with two novel NFKB1 gene mutations identified by whole-exome sequencing ( Figure 1A , B). Both patients had early onset of disease during their teenage years and presented in addition to hypogammaglobulinemia or selective IgA deficiency with a striking lack of specific antibodies (clinical characteristics are summarized in Table 1 and Supplemental Table 1 ).
Patient 1 is a now 26-year-old female who first presented with recurrent autoimmune hemolytic anemia at the age of 14. Hypogammaglobulinemia (IgG2 subclass deficiency), deficient production of specific antibodies, decreased class-switched and memory B-cells, naïve CD4-positive and regulatory T-cells, increased activated and double-negative T-cells (DNT-cells, CD4-CD8-TCRα/β+), autoimmune phenomena (hemolytic anemia, thrombocytopenia and leukopenia), lymphadenopathy, and hepatosplenomegaly were observed. She developed chronic lung disease with bronchiectases, frequent respiratory tract infections and pneumonia. Infections with viral, bacterial and fungal pathogens were frequent. She suffered from intractable abdominal pain and bloody diarrhea without evidence of infection. After a liver biopsy she developed pancolitis with subsequent sepsis and multi-organ failure and was successfully resuscitated. The patient is treated with intravenous immunoglobulin.
Steroids were intermittently given to reduce pulmonary infiltrates with partial response. Mycophenolate mofetil stabilized blood counts, but pulmonary symptoms and infections remained.
To identify the genetic cause of disease whole exome sequencing was performed for the patient and her family (Supplementary Material and Methods, Supplementary Table 2 ). A heterozygous de novo NFKB1 frameshift mutation was detected ( Figure   1A ). The NFKB1 gene encodes two proteins: p50 and its precursor p105. The shown in Figure 1E . The father and two siblings carried the same mutation, so far without clinical signs except low IgM, IgG1 and IgA levels (Supplemental Table 3 ).
Elevated levels of IgG2, IgG3 or IgG4 may compensate for lack of IgG1 in these mutation carriers.
To analyze the impact of the mutations on NF-κB mediated signaling, we tested the response to stimuli known to trigger the canonical NF-κB pathway ( Figure 2A ). We Gastrointestinal symptoms of patient 1 were reminiscent of ulcerative colitis that is acknowledged as a systemic autoimmune disease of unknown genetic cause. A candidate gene is NFKB1. 5 Susceptibility to inflammatory bowel disease can be caused by mutant NOD2 that fails to activate NF-κB in response to bacterial infection. 6 An NFKB1 promoter polymorphism (-94delATTG) leading to lower LPSinduced gene expression was described in inflammatory bowel disease. Similar to other gene defects impacting on immune system control, NFKB1 mutations lack complete penetrance. 14 In three pedigrees with 20 individuals harboring mutant NFKB1 alleles, the onset of disease varied from 2-64 years of age. Two gene carriers were completely healthy, while others had mild phenotypes with transient hypogammaglobulinemia or mild infections. 4 Gender may be a bias, because most clinically affected individuals were females (17 of 22 cases). In our patients, we did not detect mutations in possible modifier genes on the X chromosome (e.g. Foxp3, TLR7). Taking into account that our and most of the reported cases (18 of 20) were affected during or after puberty we may speculate that X-linked hormonal differences may contribute to the higher penetrance of the disease in females. In this line, one of our patients showed reduced numbers of regulatory T cells. The number of these cells can also be affected by hormonal fluctuations.
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Our results broaden the phenotypic spectrum of NFKB1 associated disease and indicate novel implications for diagnosis and treatment of patients harboring NFKB1
mutations and the therapeutic application of NF-κB directed drugs.
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Supplement Supplementary Methods
All experiments were performed after obtaining written informed consent from the patients and their families and were approved by the Ethical Review Boards of Hadassah, the Israeli Ministry of Health and the local Ethics committee of the University of Duesseldorf.
Whole-exome sequencing and bioinformatic analysis
To identify the disease causing mutations next generation sequencing was carried out after targeted enrichment of whole exonic regions from sheared genomic DNA for the patient and family members using the SureSelect Human All Exon V5+UTR kit (Agilent, Santa Clara, CA). 100 bp paired-end read sequencing was performed on a HiSeq2500
(Illumina, San Diego, CA) as recommended by the manufacturer.
Briefly, sequencing data was aligned to the human genome assembly hg19 (GRCh37) using BWA. 1 Sequencing data was converted using Samtools. 
Isolation and cultivation of primary T cells
Peripheral blood was obtained from the patients, relatives and healthy individuals.
Mononuclear cells were isolated using density gradient centrifugation and cultured in 
Transformation of primary B lymphocytes
B cell lines were generated by transformation with Epstein-Barr virus (EBV) (ATCC, Wesel, Germany) as described previously 4 and cultured in RPMI1640 supplemented with 20% FCS, 2 mM L-glutamine, 1% penicillin/streptomycin (Life Technologies).
Immunoblotting
Cells were lysed in buffer containing 1% NP-40, 50 mM Tris, pH 7.5, 350 mM NaCl, 0. and anti-CD45R (Beckman Coulter, Krefeld, Germany).
Apoptosis assay
Activated primary T cells from the patients and healthy controls were plated in 96 well plates at a density of 10 6 cells/ml and stimulated with recombinant SuperFasLigand (100 ng/ml, Enzo Life Sciences, Lörrach, Germany) in the presence or absence of LPS (100 ng/ml, Salmonella spec., supplied by Sigma-Aldrich, Deisenhofen, Germany) or TNFα (10 ng/ml, Sigma-Aldrich). After 24 h cells were stained with annexin V-FITC (BD Biosciences) and propidium iodide (PI, Sigma-Aldrich) and apoptosis was measured employing a FACSCalibur according to the manufacturer's suggestions (BD Biosciences).
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